Life Sciences

  • July 24, 2026

    Novo Asks NJ Judge To Stop Lilly's 'Deceptive' GLP-1 Ads

    Novo Nordisk Inc. asked a New Jersey federal court Friday to block rival Eli Lilly & Co. from running ads allegedly comparing their respective GLP-1 drugs using "outdated" clinical trials and "false superiority messages," arguing the ads are damaging its reputation and misleading consumers.

  • July 24, 2026

    Fenwick, Latham Lead Scribe Therapeutics' $129M IPO

    Early-stage biotechnology firm Scribe Therapeutics began trading publicly on Friday after raising $129 million in its upsized initial public offering steered by Fenwick & West LLP and Latham & Watkins LLP.

  • July 24, 2026

    Top Product Liability Cases Of 2026: Midyear Report

    In one of the most-watched cases for product liability so far this year, the U.S. Supreme Court ruled that failure-to-warn claims about the alleged cancer risks of Monsanto's widely used pesticide Roundup are barred by federal law. Social media titans were also rocked by the first verdicts delivered in cases alleging mental health harms to youth.

  • July 24, 2026

    CVS Seeks Toss Of Hospitals' 340B Suits In NY, Mich.

    CVS urged New York and Michigan federal courts to toss separate suits brought by hospital operators accusing the health giant of diverting savings from the federal 340B Drug Pricing Program to itself, saying the suits purport to raise key questions about the program when they actually concern simple contract disputes.

  • July 24, 2026

    Former Drug Co. Akorn Gets OK For $18.5M Ch. 7 Settlement

    A Delaware bankruptcy judge has signed off on a deal resolving a $28.3 million claim by the buyer of defunct drug developer Akorn's assets, allowing an $18.5 million claim in the Chapter 7 case.

  • July 23, 2026

    Texas Panel Overturns Abortion Injunction Against Midwife

    A Texas appellate court overturned a temporary injunction against a licensed Houston-area midwife accused by state prosecutors of violating Texas' abortion ban, finding Thursday a trial court wrongly admitted probable-cause affidavits from a related criminal case.

  • July 23, 2026

    AstraZeneca Immune In Vax Trial Contract Suit, 10th Circ. Says

    The Tenth Circuit on Thursday overturned a lower court ruling that AstraZeneca lacked immunity from an experimental COVID-19 vaccine trial participant's lawsuit seeking medical compensation after she suffered debilitating injuries, saying a federal statute providing immunity for vaccine developers covers her contract breach claims.

  • July 23, 2026

    Abbott Labs Accused Of Lax Security Over Shinyhunters Hack

    Abbott Laboratories and Exact Sciences were hit with a proposed class action in Illinois federal court Wednesday over a cyberattack carried out by a notorious ransomware gang known as "Shinyhunters" that absconded with patients' medical records, which the suit says is far more harmful than standard identity theft.

  • July 23, 2026

    Mo. Panel Says Exclusion Bars Mallinckrodt Opioid Coverage

    A Missouri appellate court upheld a win for a group of insurers on their arguments that a "your products" policy exclusion applied to bar coverage of alleged damages from drugmaker Mallinckrodt's unbranded marketing of opioid products.

  • July 23, 2026

    Kirkland, Sullivan & Cromwell Steer $2B ArisGlobal Deal

    Dassault Systèmes has agreed to acquire ArisGlobal, an AI-driven software provider for the life sciences industry, from private equity firm Nordic Capital for up to $2 billion, the companies said Thursday.

  • July 23, 2026

    Philly Judge Says Keller Postman Slowing Zantac Litigation

    A Pennsylvania state court judge has said Keller Postman LLC's "crusade" to remove him from presiding over several matters has ground to a halt the Zantac cancer mass tort in Philadelphia, leaving the plaintiffs' cases to "languish."

  • July 23, 2026

    J&J's Delays Should End $25M Asbestos Appeal, Builder Says

    A western Massachusetts real estate developer has asked a Connecticut appeals court to toss Johnson & Johnson's appeal of a $25 million asbestos cancer verdict in his favor, saying the company has yet to file an opening brief despite receiving five deadline extensions.

  • July 22, 2026

    J&J Talc Plaintiffs Must Back Up Cancer Link Or Risk MDL

    Plaintiffs alleging Johnson & Johnson's talcum powder products caused ovarian cancer must show they can offer expert opinions on the link between the disease and talc use or risk having their lawsuits tossed, a New Jersey federal judge ruled Wednesday.

  • July 22, 2026

    Late Emails Undercut BCBS Pricing Suit, Walgreens Says

    Walgreen Co. is urging an Illinois federal judge to again sanction a Blue Cross Blue Shield insurer and its subsidiary for allegedly failing to produce key email evidence the pharmacy retailer says "upends" the insurers' 6-year-old claim that it intentionally overcharged them for prescription drugs.

  • July 22, 2026

    Organ Network, Hospital Sued Over Racial Kidney Criteria

    A kidney disease patient launched a proposed class action in Washington federal court Tuesday accusing the United Network for Organ Sharing and Seattle hospital operator Swedish Health Services of using a flawed race-based adjustment when scoring kidney functioning, hindering Black patients' chances of getting a transplant for years.

  • July 22, 2026

    TransMedics Sheds Some Claims In Organ Transfer Biz Suit

    A Massachusetts federal judge on Tuesday significantly trimmed a proposed shareholder class action alleging that medical technology company TransMedics Inc. and its top brass made misleading statements about the success and cost-effectiveness of its organ donation products and services.

  • July 22, 2026

    Boston Scientific Settles With Stryker In Spine Device IP Fight

    Boston Scientific and Stryker Corp. have reached a settlement to resolve a case in New Jersey federal court over Stryker's alleged efforts to create a back pain device that infringed a Boston Scientific patent.

  • July 22, 2026

    Safety-Net Clinics Defend Insulin Suit Revival To Justices

    Safety-net healthcare providers urged the U.S. Supreme Court not to take on the revival of their proposed antitrust class action against Sanofi-Aventis, Eli Lilly, Novo Nordisk and AstraZeneca, arguing Wednesday that the Second Circuit's decision was based on neither mere trade group lobbying nor any kind of overcharge.

  • July 22, 2026

    Candid Health Wraps $120M Series D Funding Round

    Autonomous revenue cycle management platform Candid Health, advised by Lowenstein Sandler LLP, on Wednesday revealed that it raised $120 million in its latest funding round, marking a three-times increase in valuation over the San Francisco-based company's previous funding round in February 2025.

  • July 22, 2026

    Fed. Circ. Panel Stands By Invalidated Spinal Fusion IP

    The Federal Circuit on Wednesday said it won't rethink a panel's decision invalidating patent claims covering parts used to make expandable implant devices in spinal fusion surgeries that were the basis of a $9.5 million jury verdict against Life Spine Inc.

  • July 22, 2026

    2 Charged In Alleged $52.7M COVID-19 Tax Scheme

    Two men have been indicted in Pennsylvania on allegations that they participated in a multistate conspiracy to bilk the government out of $52.7 million in a COVID-19-related false tax return scheme, according to federal prosecutors.

  • July 22, 2026

    Squires Grants 4 IPRs, Issues No Discretionary Denials

    U.S. Patent and Trademark Office Director John Squires has granted four more petitions for inter partes review, bringing his institution rate to just shy of 30%.

  • July 22, 2026

    Goodwin, K&L Gates Steer $1.5B Repligen Gene Therapy Deal

    Repligen said Wednesday it will acquire BioLife Solutions in a cash-and-stock transaction valued at about $1.5 billion, expanding its presence in the fast-growing cell and gene therapy market, with Goodwin Procter LLP advising Repligen and K&L Gates LLP representing BioLife.

  • July 22, 2026

    Judge Skeptical Of Harm From Chinese Military Co. Label

    A D.C. federal judge on Wednesday appeared skeptical of a Chinese pharmaceutical company's claims that it has suffered irreparable damage from the U.S. Department of Defense's recommendation that it be designated a "Chinese military company."

  • July 22, 2026

    Gene Therapy Co. Inks Better Ch. 11 Financing Deal

    Sangamo Therapeutics on Wednesday told a Delaware bankruptcy judge it has negotiated new Chapter 11 financing that will provide the biotechnology company with more money at a lower interest rate and asked permission to take out the new loan.

Expert Analysis

  • Series

    Playing Piano Makes Me A Better Lawyer

    Author Photo

    Playing piano and practicing law share many parallels relating to managing complexity: Just as hearing an entire musical passage in my head allows me to reliably deliver the message, thinking about the audience's impression helps me create a legal narrative that keeps the reader engaged, says Michael Shepherd at Fish & Richardson.

  • 3 Cases Highlight SEC Distinction Between Exec, Co. Liability

    Author Photo

    Three recent enforcement actions against Spero Therapeutics, Lottery.com and Archer-Daniels-Midland demonstrate that while public companies are subject to liability for misrepresentations, the U.S. Securities and Exchange Commission is focused on individual liability when disclosure violations involve so-called half-truths, say attorneys at Cooley.

  • AI-Generated Doc Ruling Guides Attys On Privilege Risks

    Author Photo

    A New York federal court's ruling, in U.S. v. Heppner, that documents created by a defendant using an artificial intelligence tool were not privileged, can serve as a guide to attorneys for retaining attorney-client or work-product privilege over client documents created with AI, say attorneys at Sher Tremonte.

  • The Law Firm Merger Diaries: Leadership Strategy After Day 1

    Author Photo

    For law firm leaders, ensuring a newly combined law firm lives up to its promise, both in its first days of operation and well after, includes tough decisions, clear and specific communication, and cheerleading, says Peter Michaud at Ballard Spahr.

  • Record FCA Recoveries Signal Intensified Healthcare Focus

    Author Photo

    In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.

  • Fed. Circ. In Jan.: On The Validity Of Expert Testimony

    Author Photo

    The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.

  • Calif.'s Civility Push Shows Why Professionalism Is Vital

    Author Photo

    The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.

  • A Potential Shift In FDA's Approach To Drug Trial Design

    Author Photo

    Recent guidance released by the U.S. Food and Drug Administration clarifying how Bayesian approaches — which combine prior knowledge with new data — may be used in clinical trials reflects the agency's continued interest in innovative trial designs that may accelerate drug approvals, say attorneys at Alston & Bird.

  • Series

    Trivia Competition Makes Me A Better Lawyer

    Author Photo

    Playing trivia taught me to quickly absorb information and recognize when I've learned what I'm expected to know, training me in the crucial skills needed to be a good attorney, and reminding me to be gracious in defeat, says Jonah Knobler at Patterson Belknap.

  • What FDA Guidance Means For Future Of Health Software

    Author Photo

    Two significant final guidance documents released by the U.S. Food and Drug Administration last month reflect a targeted effort to ease innovation friction around specific areas, including singular clinical decision support recommendations and sensor-based wearables, while maintaining established regulatory boundaries, say attorneys at Covington.

  • Opinion

    Federal Preemption In AI And Robotics Is Essential

    Author Photo

    Federal preemption offers a unified front at a decisive moment that is essential for safeguarding America's economic edge in artificial intelligence and robotics against global rivals, harnessing trillions of dollars in potential, securing high-skilled jobs through human augmentation, and defending technological sovereignty, says Steven Weisburd at Shook Hardy.

  • Series

    Law School's Missed Lessons: What Cross-Selling Truly Takes

    Author Photo

    Early-career attorneys may struggle to introduce clients to practitioners in other specialties, but cross-selling becomes easier once they know why it’s vital to their first years of practice, which mistakes to avoid and how to anticipate clients' needs, say attorneys at Moses & Singer.

  • Drafting Tech Patents After USPTO's Eligibility Memos

    Author Photo

    Two recent U.S. Patent and Trademark Office memos on subject matter eligibility declarations provide an evidentiary playbook for artificial intelligence and software patent applications, highlighting how targeted, stand‑alone SMEDs that present objective, claim‑anchored facts can improve patent application outcomes, say attorneys at Reed Smith.

  • How State FCA Activity May Affect Civil Fraud Enforcement

    Author Photo

    A growing trend of state attorneys general enforcing their False Claims Act analogues independently of the U.S. Department of Justice carries potential repercussions for civil fraud enforcement and qui tam litigation considerations, say Li Yu at Bernstein Litowitz, Ellen London at London & Naor and Gwen Stamper at Vogel Slade.

  • Series

    Judges On AI: Practical Use Cases In Chambers

    Author Photo

    U.S. Magistrate Judge Allison Goddard in the Southern District of California discusses how she uses generative artificial intelligence tools in chambers to make work more efficient and effective — from editing jury instructions for clarity to summarizing key documents.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.